Celldex Therapeutics (NASDAQ:CLDX) Trading Down 5.5% – Time to Sell?

Celldex Therapeutics, Inc. (NASDAQ:CLDX)’s stock price fell 5.5% during mid-day trading on Monday . The stock traded as low as $20.06 and last traded at $20.10. 889,296 shares changed hands during mid-day trading, a decline of 5% from the average session volume of 937,358 shares. The stock had previously closed at $21.26.

Wall Street Analysts Forecast Growth

CLDX has been the topic of a number of analyst reports. UBS Group decreased their price objective on Celldex Therapeutics from $44.00 to $38.00 and set a “buy” rating on the stock in a research note on Friday, May 9th. HC Wainwright reiterated a “buy” rating and set a $50.00 price target on shares of Celldex Therapeutics in a report on Friday. The Goldman Sachs Group decreased their target price on shares of Celldex Therapeutics from $36.00 to $31.00 and set a “neutral” rating on the stock in a research report on Friday, May 9th. Canaccord Genuity Group initiated coverage on Celldex Therapeutics in a research note on Monday, April 28th. They set a “buy” rating and a $64.00 price target on the stock. Finally, Morgan Stanley decreased their price target on Celldex Therapeutics from $46.00 to $43.00 and set an “overweight” rating on the stock in a research note on Friday, May 9th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $50.90.

Celldex Therapeutics Stock Performance

The company has a market capitalization of $1.35 billion, a PE ratio of -7.91 and a beta of 1.33. The company has a 50 day moving average price of $19.43 and a 200 day moving average price of $21.71.

Celldex Therapeutics (NASDAQ:CLDX) last issued its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. The firm had revenue of $0.70 million during the quarter, compared to analyst estimates of $1.08 million. On average, equities analysts forecast that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Celldex Therapeutics

Institutional investors have recently modified their holdings of the business. EverSource Wealth Advisors LLC grew its position in shares of Celldex Therapeutics by 215.7% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 878 shares during the last quarter. GAMMA Investing LLC boosted its position in shares of Celldex Therapeutics by 6,665.9% in the 1st quarter. GAMMA Investing LLC now owns 2,977 shares of the biopharmaceutical company’s stock valued at $54,000 after purchasing an additional 2,933 shares during the period. Headlands Technologies LLC purchased a new position in Celldex Therapeutics in the 4th quarter worth about $81,000. AlphaQuest LLC raised its holdings in Celldex Therapeutics by 171.0% during the 4th quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company’s stock worth $108,000 after buying an additional 2,705 shares during the period. Finally, Aquatic Capital Management LLC acquired a new stake in Celldex Therapeutics during the 4th quarter worth about $121,000.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.